ResearchPod Summary
In vitro maturation (IVM) is a clinical technique designed to mature immature oocytes outside the body, offering an alternative or supplement to conventional in vitro fertilization (IVF). Despite its application for over 50 years, IVM uptake remains low. This is primarily attributed to a lack of consensus on definitions, protocol variations, and difficulties in comparing clinical outcomes across different centers. This review consolidates current knowledge, examines the biological basis of oocyte maturation, and explores future applications in fertility preservation and complex infertility cases.
The core challenge in IVM is the synchronization of nuclear and cytoplasmic maturation. In vivo, this process is governed by complex signaling pathways, including the cyclic adenosine monophosphate (cAMP) and C-type natriuretic peptide (CNP) systems, which prevent premature meiosis resumption. Traditional IVM often lacks these regulatory signals, leading to desynchronized maturation and suboptimal oocyte quality.
Recent advancements focus on mimicking the in vivo environment through two primary approaches:
IVM is increasingly recognized as a vital strategy for specific patient populations, including those with polycystic ovary syndrome (PCOS), diminished ovarian reserve (DOR), and resistant ovarian syndrome. Furthermore, it is a key tool in oncofertility, where it allows for fertility preservation even in cases with limited time for conventional ovarian stimulation. The authors argue that future progress requires international collaboration, the standardization of media compositions, and rigorous long-term follow-up to address safety concerns regarding epigenetic and DNA imprinting integrity.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.